Search This Blog

Friday, January 29, 2021

RedHill Gets Positive Review for Phase 2/3 COVID-19 Study of Opaganib

 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib[1] in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

https://www.biospace.com/article/releases/redhill-biopharma-announces-positive-dsmb-futility-review-for-phase-2-3-covid-19-study-of-opaganib/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.